A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Status:
Completed
Trial end date:
2021-03-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of lenvatinib in participants with
recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).